Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
Carella
A M
AM
Santini
G
G
Martinengo
M
M
Nati
S
S
Giordano
D
D
Congiu
A
A
Cerri
R
R
Damasio
E
E
Risso
M
M
Rossi
E
E
D000208:Acute Disease; D000609:Aminoacridines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000008:administration & dosage*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine; D005047:Etoposide; D011034:Podophyllotoxin; D001374:Azacitidine